A randomized, open-label, cross-over pharmacokinetic study of dacarbazine in combination with Genasense [oblimersen] in subjects with advanced melanoma.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2012
At a glance
- Drugs Dacarbazine; Oblimersen
- Indications Malignant melanoma
- Focus Pharmacokinetics
- 12 Mar 2012 Actual end date (1 Sep 2007) added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2007 New trial record.